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ABSTRACT:  
Fluorescence imaging is one of the most versatile and widely used visualization 
methods in biomedical research. However, tissue autofluorescence is a major obstacle 
confounding interpretation of in vivo fluorescence images. The unusually long emission 
lifetime (5-13 µs) of photoluminescent porous silicon nanoparticles can allow the time-gated 
imaging of tissues in vivo, completely eliminating shorter-lived (< 10 ns) emission signals 
from organic chromophores or tissue autofluorescence. Here, using a conventional animal 
imaging system not optimized for such long-lived excited states, we demonstrate 
improvement of signal to background contrast ratio by > 50-fold in vitro and by > 20-fold 
in vivo when imaging porous silicon nanoparticles. Time-gated imaging of porous silicon 
nanoparticles accumulated in a human ovarian cancer xenograft following intravenous 2 
 
injection is demonstrated in a live mouse.  The potential for multiplexing of images in the 
time domain by using separate porous silicon nanoparticles engineered with different 
excited state lifetimes is discussed. 
 
 
MAIN TEXT:  
Fluorescence imaging has become a dominant in vitro and in vivo visualization method in 
biomedical research due to its high sensitivity, its high spatial resolution, and its ease of use
1, 2. 
In vivo imaging of exogenous fluorescent probes that target diseased tissues has also shown 
promising results in clinical settings, such as the early detection of breast cancer, the outlining of 
tumor margins during surgery, and endoscopic diagnosis of cancer micrometastasis
1, 3-5. 
However, the method is limited by tissue attenuation (scattering and absorption of the excitation 
or the emission light) and by tissue autofluorescence
6, 7.  To minimize tissue attenuation effects, 
researchers have concentrated on near-infrared (NIR) fluorophores that are excited and emit in 
the spectral window between wavelengths of 650 - 950 nm
8-11. However, tissue autofluorescence 
still produces a substantial background signal in this spectral range that severely limits the 
quality of images, especially when very low concentrations of the fluorescent probe accumulate 
at the target site
12.   
 
The endogenous fluorophores responsible for tissue autofluorescence have decay 
lifetimes of ~ 1 - 10 ns, depending on the type of tissue
7. It has been proposed that late time-
gating (i.e., capturing the signal at a delayed time after excitation) could be used to image 
molecular or quantum dot imaging probes in the presence of this interference
13-18. However, 3 
 
there is a lack of biocompatible NIR fluorophores with fluorescence lifetimes significantly 
greater than 1-10 ns, due to the quantum mechanical selection rules associated with organic 
molecules or direct gap semiconductors
7, 19.   
 
Electrochemically etched porous silicon has shown considerable potential for in vivo 
applications due to its biodegradability, its low toxicity, its large specific capacity for drug 
loading, and its intrinsic photoluminescence
20-27. Silicon is an indirect gap semiconductor, which 
gives it a much longer-lived excited state than direct gap semiconductors such as CdS or CdSe
28.  
This property translates to the scale of quantum dots, and nanoparticles derived from silicon tend 
to display radiative lifetimes on the order of 100 ns to several microseconds
29-31. In contrast, CdS 
and CdSe excited states decay on much shorter timescales of a few nanoseconds to several tens 
of nanoseconds
32. We recently demonstrated that NIR luminescent nanoparticles made of porous 
silicon (LPSiNPs) can be prepared that are biocompatible, have low systemic toxicity, and that 
accumulate in tumors in vivo and then degrade into components cleared by the kidneys
33.  
 
Here, we show that the emission lifetime of these nanoparticles is sufficiently long (5 -13 
μs) to permit late time-gated imaging. The persistent emission from LPSiNPs is well 
differentiated in the time domain from signals associated with tissue autofluorescence or 
interfering organic chromophores. Delayed (late time-gated) images acquired 18 ns after 
excitation show clear signals from LPSiNPs, while the background fluorescence has disappeared 
due to its much shorter lifetime. An example of the utility of the method is demonstrated in the 
imaging of a human ovarian cancer xenograft in a mouse model, using LPSiNP probes 
introduced via intravenous injection. 4 
 
 
RESULTS 
Long emission lifetime of LPSiNPs. LPSiNPs were prepared by electrochemical etching of 
single-crystal Si in HF-containing electrolyte, followed by lifting-off of the porous layer, 
ultrasonic fracture, filtration of the resulting nanoparticles through a 0.22 µm filter membrane, 
and finally activation of photoluminescence by treatment in an aqueous solution following the 
published procedure
33.  The emission lifetime of the nanoparticles was controlled by adjusting 
the current density used in the electrochemical etch (Fig. 1a and Supplementary Figs S1 and S2) 
and by post-etching chemical treatments (Supplementary Table S1). For the time-gated 
fluorescence imaging study presented here, the LPSiNPs were prepared using electrochemical 
etching at a current density of 200 mA/cm
2 with a two-week aqueous activation treatment. The 
nanoparticles were coated with 5 kDa polyethylene glycol (PEG) by reaction with a PEG-silane 
(PEG-LPSiNP, Fig. 1b). The mean hydrodynamic diameter of the PEG-LPSiNP formulation 
(measured by dynamic light scattering, DLS) was 168 nm, consistent with transmission electron 
microscopy (TEM) measurements (Supplementary Fig. S3).  The photoluminescence spectrum 
from the PEG-LPSiNPs (λex = 370 nm) appeared at wavelengths between 600 and 900 nm (Fig. 
1c), and the decay lifetime was 12 µs (λem = 650 nm, 22 ºC).  This lifetime is >1000 times larger 
than that typical of tissue autofluorescence or common fluorescent imaging dyes (Fig. 1, d and e; 
Supplementary Fig. S4, S5).  
 
We first tested whether the long-lived photoluminescence from PEG-LPSiNPs could be 
separated from the fluorescence of conventional fluorophores in the time domain. To 5 
 
demonstrate the potential for practical applications, we used a commercial in vivo imaging 
system (eXplore Optix, ART Inc.).  This instrument uses pulsed laser diodes and time-correlated 
single photon counting (TCSPC) to quantify fluorescence intensity and lifetime
34.  When imaged 
using a 470 nm excitation laser and a 590 nm longpass emission filter, the intensity of 
fluorescence from an aqueous solution 10 µg/mL of the common imaging dye Cy3.5 was 
comparable to the intensity of photoluminescence from an aqueous suspension 100 µg/mL in 
PEG-LPSiNPs (Fig. 2a). The laser we used operates at a repetition rate of 40 MHz, 
corresponding to a time window between pulses of 25 ns. The duration of an individual pulse 
from the laser is < 0.1 ns.  Although the Cy3.5 sample and the PEG-LPSiNP sample showed 
similar photoluminescence intensity when integrated over the entire 25 ns window (Fig. 2a), 
temporally integrating a 1 nanosecond gate of the signal between 20.5 and 21.5 ns of the imaging 
window (18 and 19 ns post-pulse after correcting for synchronization) yielded a strong signal 
from the PEG-LPSiNP sample (50 times greater than background), while the signal from the 
Cy3.5 sample was at or below the noise level of the instrument (Fig. 2, b and c).  This 
improvement in image contrast is due to the rapid decay of fluorescence from the organic 
fluorophore (0.6 ns lifetime); the photoluminescence signal from the nanoparticle is essentially 
constant for the duration of the 25 ns period between pulses (Fig. 2b). As a result, only the PEG-
LPSiNP sample was visible under late time-gating conditions (Fig. 2c). 
 
In vivo time-gated imaging with PEG-LPSiNPs. We next investigated the possibility of 
eliminating tissue autofluorescence or interference from exogenous fluorophores when imaging 
PEG-LPSiNPs in vivo. A 20 µL aliquot of PEG-LPSiNPs (0.5 mg/mL) and a 20 µL aliquot of 
Cy3.5 (0.02 mg/mL) in normal saline were injected subcutaneously into the right and left 6 
 
shoulder of a nude mouse, respectively (Fig. 2d). When imaged under pseudo continuous wave 
(CW), or steady-state conditions (i.e., no time gating), the two injection points had intensities 
comparable to the brighter autofluorescent tissues (Fig. 2e). However, the intensity-time decay 
curves of the relevant regions revealed a distinct persistence of signal only for the PEG-LPSiNPs 
(Fig. 2g). As shown in Fig 2g, the fast decay component (dominant at times <5 ns) from 
ubiquitous tissue autofluorescence appeared similar in all the body regions imaged: the PEG-
LPSiNP injection site (T1), the Cy3.5 injection site (T2), and the background tissue region (T3). 
Only at the site of PEG-LPSiNP injection was residual photoluminescence intensity observed at 
times >5ns, consistent with the longer lifetime of PEG-LPSiNPs.  As predicted by the in vitro 
data of Fig. 2b, the signal from PEG-LPSiNPs was relatively constant between ~10 and 22 ns.  
To confirm this persistent signal at the injection site arose from PEG-LPSiNPs, we measured the 
full decay in vivo on a 100 µs time scale (Supplementary Fig. S5). In agreement with the results 
in Fig. 2g, both control tissue and tissue injected with PEG-LPSiNPs showed a prompt decay 
from tissue autofluorescence (<5ns).  However, only the tissue containing PEG-LPSiNPs showed 
a slow photoluminescence decay component, consistent with the in vitro measurements of PEG-
LPSiNPs (Fig. 1d, Supplementary Fig. S5). Due to the slower radiative decay rate and low 
injection dose, this long-lived signal is weaker than the signals from Cy3.5 or from tissue 
autofluorescence, though it is easy to discern in the time-resolved data (Fig. 2g, T1). Application 
of the late time-gating algorithm (1 ns gate, 18 ns post-excitation) revealed a distinct spot in the 
PEG-LPSiNP injection point (T1), with negligible intensity from the Cy3.5 injection or from 
background tissue autofluorescence (Fig. 2f).  Simple analysis of pixel intensities revealed a 20-
fold increase in image contrast with the time-gated (TG) image relative to the CW image (Fig. 2, 
e and f). It is possible that excitation crossover (bleed-through of the excitation source scattered 7 
 
from the tissues), a common problem for in vivo fluorescence imaging, may also contribute to 
the background signals in CW fluorescence images.  Since the pulse width of the excitation laser 
was <0.1 ns, the time-gating method used here was able to remove this potential interference. 
 
PEG-LPSiNPs are distinguishable from fluorescent proteins. Genetically expressed 
fluorophores such as fluorescent proteins are widely used in biomedical research, so we next 
tested time-gated imaging of PEG-LPSiNPs in the human ovarian carcinoma 2008 cell line 
expressing the red fluorescent protein mCherry (2008-mCherry, Supplementary Fig. S6a).  The 
fluorescence lifetime of mCherry is ~1.4 ns
35, (verified in Supplementary Fig. S6b). In vitro 
imaging of PEG-LPSiNPs and 2008-mCherry cells showed that the signal from the nanoparticles 
was readily distinguishable using late time-gated imaging (Supplementary Fig. S6, c and d). 
 
The PEG-LPSiNPs were also readily distinguishable from mCherry in vivo.  A nude 
mouse bearing a 2008-mCherry tumor xenograft on each shoulder was imaged. The CW image 
displayed fluorescence from both tumors as well as strong tissue autofluorescence (Fig. 3, a and 
b). The fluorescence signal from mCherry could not be distinguished from tissue 
autofluorescence due to their similar short fluorescence lifetimes (Fig. 3b). PEG-LPSiNPs (50 
µL, 0.2 mg/mL) were then injected into the tumor on the right shoulder of the mouse, and the 
mouse was imaged again under CW conditions. The tumor injected with nanoparticles was 
brighter than the control tumor in the CW image, but tissue autofluorescence and the signal from 
the control tumor were still clearly visible (Fig. 3c).  In contrast, signals from both the control 
tumor and tissue autofluorescence were completely eliminated in the time-gated image (Fig. 3c). 
Ex vivo fluorescence images confirmed the presence of PEG-LPSiNPs in the tumor, and they 8 
 
demonstrated the effectiveness of time-gated imaging of PEG-LPSiNPs in ex vivo tissues (Fig. 3, 
d-f).  
 
Time-gated imaging of tumors with PEG-LPSiNPs. Finally, we evaluated the potential of 
imaging tumors using intravenously injected circulating PEG-LPSiNPs as the photoluminescent 
probe.  Intravenously injected nanoparticles can passively accumulate in tumor tissues due to the 
enhanced permeability and retention (EPR) effect
36-38. However, the efficiency of this process is 
low and generally only a small fraction of injected nanoparticles accumulates in a tumor
39, 40. 
This creates a challenge for in vivo optical imaging because tissue autofluorescence can 
overwhelm the signals from the fluorescent probe. To evaluate the ability of late time-gated 
PEG-LPSiNPs to remove tissue autofluorescence in this situation, PEG-LPSiNPs (10 mg/kg) 
were injected intravenously into a nude mouse bearing a human ovarian carcinoma SKOV3 
xenograft tumor (Fig. 4a). Fluorescent images of the mouse were intermittently acquired over a 
24 h time period post-injection.  No signal from the nanoparticles was observed in either the CW 
or the TG images immediately after injection because very few nanoparticles had accumulated in 
the tumor tissue (Fig. 4b). In addition, the lifetime of autofluorescence measured from the 
xenograft tumor was 2.2 ns, similar to the lifetime of the autofluorescence from healthy tissues 
measured in the vicinity of the tumor (2.3 ns). Therefore, no tumor contrast was detected in the 
TG image if the long-lived photoluminescent PEG-LPSiNP probe was not present. Weak 
photoluminescence was detected in the tumor 1 h after injection. However, the signal from the 
nanoparticles was too weak to be differentiated from tissue autofluorescence even with time-
gating (Fig. 4c).  As time progressed more PEG-LPSiNPs accumulated at the tumor, and the TG 
image obtained 4 h post-injection clearly revealed the site of the tumor (Fig. 4d).  No contrast 9 
 
between tumor and normal tissue was observed in the CW image due to the pronounced 
autofluorescence signals.  The intensity ratio between the tumor and normal tissues increased 
from ~1 in the CW image to 3 in the TD image (Fig. 4d).  The signal from the tumor then 
decreased substantially 24 h post-injection (Fig. 4e) as the nanoparticles degraded and cleared 
from the host
33.  Ex vivo fluorescence images indicated that a small, but detectable quantity of 
PEG-LPSiNPs remained in the tumor 24 h post-injection (Supplementary Fig. S7).  
 
DISCUSSION 
Although the commercial time-domain imager used in the present study to identify and 
track the silicon-based nanoparticles has very good (sub-nanosecond) time resolution and 
excellent detector sensitivity, it is limited in the delay time that can be applied due to the 
repetition rate of the pulsed laser.  A less sophisticated imaging system, with an ability to gate at 
a modest (>50 ns or even longer) delay time, is expected to yield even better image quality from 
PEG-LPSiNPs due to the long (microseconds) emission lifetime of this probe (Fig. 1d, 
Supplementary Figs S4 and S5).  For example, given two emitters with the same steady-state 
emission intensity—a long-lived emitter such as porous Si (12 µs lifetime, 10% quantum yield) 
and a prompt-emitting fluorophore such as Cy3.5 (0.6 ns lifetime, 15% quantum yield)—the 
time-gated (1 ns window, delay of 18 ns) emission intensity of the porous Si emitter is 
theoretically >10
8 times larger than the prompt emitter. This calculation assumes single-
exponential decays and unitary instrument response functions.  The theoretical contrast ratio 
rises very quickly with delay time; if imaged at a delay of 50 ns, it is >10
31.  Even if the porous 
Si probe is present at a concentration a million fold lower than the prompt-emitting fluorophores, 
the theoretical contrast ratio at 50 ns post-excitation is >10
25. The potential sensitivity 10 
 
improvement obtained with later time-gating is especially helpful when a low dose of imaging 
probe is required. 
Typically in time resolved fluorescence imaging one must contend with temporally 
overlapping fluorescence decays from different fluorophores and unmix these signals based on 
lifetime contrast using model fitting (e.g. multiexponential fits). However, late time-gated 
imaging using long-lifetime LPSiNPs avoids the temporal overlap of confounding tissue 
autofluorescence signals, eliminating the need to measure the complete fluorescence decay and 
unmix the signals. This approach provides a means of improving detection sensitivity and image 
contrast without sacrificing image resolution or generating false readings due to potential errors 
in model assumptions. 
The wavelength distribution of the NIR emission spectrum of LPSiNPs is broader than 
many fluorescent probes, which places a limit on the use of LPSiNPs for multicolor imaging in 
the spectral domain. However, in contrast to conventional molecular probes, the decay lifetime 
of LPSiNPs can be readily tuned without changing the chemical nature of the probe, using a mild 
aqueous treatment (Supplementary Table S1).  This provides the possibility of multiplex imaging 
in the time domain using multiple nanoparticle probes and various time gates.  Furthermore, the 
slow change in emission lifetime that occurs upon degradation in aqueous media may allow the 
nanoparticle probe to report on its age in the system. In addition to their ability to provide high 
contrast images by time gating, the low toxicity and biodegradable characteristics of LPSiNPs 
overcomes the environmental and safety disadvantages of cytotoxic or non-biodegradable 
fluorescent probes currently used for in vitro or in vivo imaging.  
 
METHODS 11 
 
Preparation of PEG-LPSiNPs.  Luminescent porous silicon nanoparticles (LPSiNPs) were 
prepared following a previously described method
33, 41:  (100)-oriented p-type single-crystal Si 
wafers (0.8-1.1 mΩ-cm resistivity, obtained from Siltronix, Inc.) were electrochemically etched 
by application of a constant current density of 200 mA/cm
2 for 150 s in an electrolyte containing 
aqueous 48% hydrofluoric acid and ethanol in a 3:1 ratio. The resulting porous Si films were 
lifted from the Si substrate by application of a current pulse of 4 mA/cm
2 for 250 s in a solution 
containing 3.3% (by volume) of 48% aqueous HF in ethanol. The porous Si film was fractured 
by ultrasound and filtered through a 0.22 µm membrane. Finally, the nanoparticles were mildly 
oxidized by soaking in deionized water for 2 weeks to activate photoluminescence. The activated 
nanoparticles were rinsed with deionized water 3 times by centrifugation. LPSiNP samples were 
prepared at the following etching current densities: 50 mA/cm
2 for 300 s, 200 mA/cm
2 for 150 s, 
or 400 mA/cm
2 for 150 s. The activation step involved soaking of the LPSiNPs in deionized 
water for various periods of time: 2 weeks, 6 weeks, or 10 weeks. To prepare PEG-LPSiNPs, a 
0.6 mL aliquot of an ethanolic dispersion (0.5 mg/mL LPSiNPs) was mixed with a 0.5 mL 
aliquot of 6 mg/mL mPEG-Silane (MW 5k, Laysan Bio, Inc.) in ethanol. The mixture was stirred 
for 16 h at room temperature. The nanoparticles were rinsed 3 times with ethanol and then 3 
times with water.  The samples were collected by centrifugation between each rinsing step.  
 
Property measurements of LPSiNPs. Dynamic light scattering (Zetasizer Nano ZS90, Malvern 
Instruments) was used to determine the hydrodynamic size of the nanoparticles. Transmission 
electron microscope (TEM) images were obtained with a FEI Tecnai G
2 Sphera.  Scanning 
electron microscope (SEM) images were obtained using a Philips XL30 field emission ESEM 
operating in secondary electron emission mode. The photoluminescence (λex = 370 nm, 460 nm 12 
 
long pass emission filter) spectra of LPSiNPs or PEG-LPSiNPs were obtained using a Princeton 
Instruments/Acton spectrometer fitted with a liquid nitrogen-cooled silicon charge-coupled 
device (CCD) detector. The photoluminescence decay data for aqueous dispersions of 
nanoparticles (in water or in tissue homogenates) were acquired using a Horiba Scientific 
FluoroLog-3 spectrofluorometer using a time correlated single photon counting (TCSPC) 
method. A 456 nm NanoLED (Horiba Scientific) at 10 kHz repetition rate was used as the 
excitation source. The signal was collected at 650 or 700 nm at 22 ºC. Although the decay curves 
for the PSiNPs were nonexponential, average decay lifetime is reported as the time at which the 
photoluminescence intensity of the nanoparticles decreased to l/e of the initial value after 
excitation. For the in vivo photoluminescence decays obtained on a longer (microseconds) 
timescale (Supplementary Fig. S5), spectra were acquired using a home-built system. A 10 Hz 
pulsed Nd:YAG laser (excitation at 355 nm, Quantel) was used as the source, and the PL signal 
was recorded with a high speed Si photo detector (DET110, Thorlabs) coupled to a 400 nm 
longpass filter and an oscilloscope (DPO3054, Tektronix).  
 
Cell lines and mice. Two human ovarian carcinoma cell lines SKOV3 and 2008 were used in 
this study. 2008 cells were transduced with lentiviral vectors containing the red fluorescent 
protein mCherry sequence (pLVX-mCherry, Clontech). The cells expressing mCherry (2008-
mCherry) were sorted by flow cytometry and maintained in RPMI-1640 medium with 10% fetal 
calf serum (Invitrogen). Female nu/nu nude mice (Charles River) were maintained in specific 
pathogen-free facilities at the University of California, San Diego.  Animal protocols were 
approved by the Institutional Animal Care and Use Committee.   
 13 
 
In vitro and in vivo fluorescence imaging. A time-domain fluorescence imaging system 
eXplore Optix (ART Advanced Research Technologies, Inc.) was used to image fluorophore 
solutions and cell suspensions in vitro, and mice in vivo. A 470 nm laser with 40 MHz repetition 
rate was used as the excitation source and a 590 nm longpass filter was used as the emission 
filter for all imaging experiments. 
For in vitro comparison of PEG-LPSiNPs and Cy3.5, an aliquot of PEG-LPSiNPs in 
aqueous dispersion (50 µL, 0.1 mg/mL) was placed in a microtube, and an aliquot of Cy3.5 NHS 
ester (GE Healthcare) in aqueous solution (50 µL, 0.01 mg/mL) was placed in a separate 
microtube.  The microtubes were placed next to each other and imaged at the same time with the 
Optix imaging system. For in vivo imaging, PEG-LPSiNPs (20 µL, 0.5 mg/mL) and Cy3.5 (20 
µL, 0.02 mg/mL) were injected subcutaneously into the right and left shoulder of a nude mouse, 
respectively. The mouse was imaged with the Optix imaging system immediately after injection. 
For in vitro comparison of PEG-LPSiNPs with mCherry, aliquots of PEG-LPSiNPs (20 
µL, 0.2 mg/mL) and 2008-mCherry cell suspension (20 µL, ~1 million cells) were placed in 
separate microtubes and imaged at the same time with the Optix imaging system. For in vivo 
imaging, a nude mouse bearing a 2008-mCherry tumor (~0.7 cm) on each side of the shoulder 
was used. An aliquot of PEG-LPSiNPs dispersion (50 µL, 0.2 mg/mL) was injected into the 
tumor on the right shoulder of the mouse, and the mouse was imaged with the Optix imaging 
system immediately after injection. 
Nude mice bearing a SKOV3 tumor (~0.5 cm, left flank) were used for the in vivo tumor 
imaging study. A PEG-LPSiNPs saline dispersion was injected intravenously into the mouse at a 
dose of 10 mg/kg body mass through the tail vein. The mouse was imaged at several different 14 
 
time points for 24 h post-injection. The tumor and muscle in the vicinity of the tumor were 
harvested and imaged 24 h after injection. 
 
Data analysis and time gating. The Optix imaging system data were analyzed using OptiView 
(ART Advanced Research Technologies, Inc.) to calculate the in vivo decay lifetimes of the 
fluorophores or tissue autofluorescence. Continuous wave (CW) fluorescence images were 
obtained by reconstructing the photoluminescent signal collected within the full 25 ns imaging 
time-window from the data using MATLAB (MathWorks, Inc.). Time-gated (TG) fluorescence 
images were generated by extracting and temporally integrating the photoluminescent signal 
collected between 20.5 and 21.5 ns of the imaging time-window (18-19 ns after the excitation 
pulse) from the data using a subroutine in the computer program MATLAB.   
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Figure 1 | Characterization of polyethylene glycol-conjugated luminescent porous silicon 
nanoparticles. a, Hydrodynamic diameter, surface chemistry, and emission lifetime of LPSiNPs 
prepared at the indicated etch current densities. b, Schematic diagram depicting the PEG surface 
chemistry on the LPSiNPs. Photograph of PEG-LPSiNPs in water, obtained under UV light 
illumination. c, Absorbance and steady-state photoluminescence spectrum of PEG-LPSiNPs (λex 
= 370 nm). d, Normalized photoluminescence intensity-time trace for PEG-LPSiNPs after pulsed 
excitation (λex = 456 nm, λem = 650 nm, 22 ºC). e, Fluorescence lifetimes of commonly used 
fluorophores and tissue autofluorescence
7, 42.  20 
 
 
Figure 2 | Comparison of time-domain fluorescence characteristics of PEG-LPSiNPs and 
the common imaging fluorophore Cy3.5.  a, Steady-state, or continuous wave (CW) 
fluorescence images of Cy3.5 (0.01 mg/mL) and PEG-LPSiNPs (0.1 mg/mL) samples in 
microtubes (λex = 470 nm, λem = 590 nm longpass).  b, Normalized intensity decay of the 
fluorescence/photoluminescence signals from the Cy3.5 and PEG-LPSiNPs samples shown in 
(a) as a function of time after excitation pulse. The vertical orange bar depicts the time window 
used in the time-gating algorithm (20.5-21.5 ns of the 25 ns imaging window, which is 18-19 ns 
after excitation pulse) to obtain time-gated (TG) fluorescence images; i.e., the images depicted as 
“TG” represent fluorescence intensity integrated between 18-19 ns after the excitation pulse. c, 
TG image of the same microtubes in (a).  The image of the Cy3.5 sample almost completely 
disappears due to its short-lived emission. d, Bright field image of a nude mouse injected 
subcutaneously with PEG-LPSiNPs (20 µL, 0.5 mg/mL) and Cy3.5 (20 µL, 0.02 mg/mL). The 
arrow indicates the injection site of PEG-LPSiNPs, and the arrowhead indicates the injection site 
of Cy3.5. e, CW fluorescence image of the region of the mouse indicated by the white box in (d), 
obtained with the Optix imaging system. Regions identified as T1, T2, and T3 are the injection 
site of PEG-LPSiNPs, the injection site of Cy3.5, and the abdomen, respectively.  f, TG image of 21 
 
the same region shown in (e).  Signals from the Cy3.5 dye (T2) and from tissue autofluorescence 
(T3) almost disappear. The intensity ratio of PEG-LPSiNPs to tissue autofluorescence was 
calculated by comparing the CW to the TG signal intensities of PEG-LPSiNPs (T1, arrow) and 
tissue autofluorescence (T3, hollow arrow) as indicated in (e). g, Normalized intensity decay of 
the fluorescence signals from T1, T2, and T3 in (e), as indicated. The vertical orange bar depicts 
the time window used in the time-gating algorithm for (f).  22 
 
 
Figure 3 |  Time-gated fluorescence images comparing PEG-LPSiNP with fluorescent 
protein mCherry in a nude mouse bearing mCherry-expressing tumors.  a, Bright field 
photograph of mouse containing two tumors, one on each shoulder.  Tumors are indicated with 
white arrows. b, CW and TG (as defined in Fig. 2) fluorescence images of the tumors, showing 
low differentiation of the expressed mCherry and tissue autofluorescence in the time-domain. c, 
CW and TG fluorescence images of the tumors after injection of PEG-LPSiNPs (50 µL, 0.2 
mg/mL) into the right shoulder tumor (on the top of the image, indicated with dashed white 
circle). d, Ex vivo bright field image of the PEG-LPSiNP-injected tumor (T
+), a control tumor 
(T
-)
, and muscle tissue excised from the animal post-injection. e, CW fluorescence image of the 
excised tissues in (d). f, TG fluorescence image of the tissues in (d). 
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Figure 4 | Time-gated fluorescence images of mouse bearing SKOV3 xenograft tumor after 
IV injection of PEG-LPSiNPs. a, Bright field image of a nude mouse bearing a tumor at the 
flank. The arrow indicates the site of the tumor. b-e, CW and TG (as defined in Fig. 2) 
fluorescence images of the region indicated with the white box in (a) immediately (b), 1h (c), 4 h 
(d), or 24 h (e) post-injection of PEG-LPSiNPs (10 mg/kg body weight). The signal to 
background (tissue autofluorescence) ratio described in the text was calculated by comparing 
signal intensities at the sites indicated by the black asterisk (PEG-LPSiNPs) and the black circle 
(tissue autofluorescence) as indicated in (d) in both CW and TG images.  
 
 